Depo-Provera MDL update: the July court count and what it means for meningioma claims

A lot of Depo-Provera lawsuit updates sound like they were
written for lawyers. That is not much help when what you
really want to know is simpler: Is this case still moving?
What records matter? What should I do if I used the shot
and later found out I had a meningioma?

We checked the current court reports, the FDA label, and
the medical literature before writing this update.

The short version: the Depo-Provera meningioma litigation
is now a large federal MDL. The Judicial Panel on
Multidistrict Litigation lists MDL No. 3140, In re: Depo-
Provera (Depot Medroxyprogesterone Acetate) Products
Liability Litigation, in the Northern District of Florida
before Judge M. Casey Rodgers. The JPML's July 1, 2026
actions-pending report lists 5,830 pending federal actions
in that MDL.

That number does not prove anyone's individual case. It
also does not mean a settlement check is around the
corner. But it does show that the litigation has moved
well beyond the first wave of filings. Thousands of people
are now in one coordinated federal proceeding, and the
court is working through shared evidence and expert issues
that could affect many claims.

The injury at the center of the cases

A meningioma is a tumor that starts in the meninges, the
layers of tissue around the brain and spinal cord.
Cleveland Clinic describes meningiomas as the most common
type of brain tumor. Many are called benign, which can
make the diagnosis sound less serious than it feels in
real life.

Benign does not always mean easy.

Depending on where the tumor is and how it grows, a person
may deal with headaches, vision changes, hearing problems,
seizures, balance problems, surgery, radiation, repeat
MRIs, and years of follow-up appointments. Some people go
back to work quickly. Others do not. The medical story
varies a lot from one family to the next.

The lawsuits focus on people who received Depo-Provera or
a related medroxyprogesterone acetate injection and later
received a meningioma diagnosis. Many lawyers screening
these cases pay close attention to repeated injections and
longer use histories, because that is where much of the
warning-label language now points.

The FDA label now says meningioma

The current FDA labeling for Depo-Provera CI and depo-subQ
provera 104 includes a meningioma warning. The label says
cases of meningiomas have been reported after repeated
administration of medroxyprogesterone acetate, primarily
with long-term use. It also tells healthcare professionals
to monitor patients for signs and symptoms of meningioma
and to discontinue the product if a meningioma is
diagnosed.

That is not lawsuit hype. It is label language.

For someone still using Depo-Provera, the practical point
is medical first, legal second. If you have a meningioma
history, new neurological symptoms, or a concern about
continued use, talk with your doctor. Do not stop or
change a medication plan because of a blog post.

Why the BMJ study is getting attention

One study keeps coming up in these cases: a 2024 national
case-control study published in the BMJ and indexed by
PubMed. It looked at selected progestogens and the risk of
intracranial meningioma in France. The study included
medroxyprogesterone acetate, the active drug in Depo-
Provera, among the progestogens reviewed.

No single study wins a lawsuit by itself. Courts still
look at expert testimony, medical records, prescribing
history, company documents, dosage, timing, and other
possible explanations. Still, the BMJ paper is part of why
the science is being watched so closely.

The court calendar matters, but it is not a promise

You may see two words in Depo-Provera updates: Daubert and
bellwether.

Daubert is the expert-testimony gate. The judge decides
whether certain expert opinions are reliable enough for a
jury to hear. In a drug-injury case, that can include
opinions about whether the product can cause the injury
alleged in the lawsuits.

A bellwether trial is an early test trial. It does not
decide every other case. It can, however, give both sides
a better sense of how juries react to the evidence.

Public litigation updates have reported general-causation
Daubert activity around late June 2026 and a first
bellwether trial date that had been expected in December

1. Schedules in MDLs can change. When they do, it is

usually because the parties are fighting over expert
evidence, working through discovery, or discussing
resolution. A changed date by itself is not proof that
cases are won, lost, or settled.

Be careful with anyone who tells you otherwise.

Records that make the first review easier

You do not need a perfect file before asking for help. But
if you can gather a few records, the review usually gets
sharper:

• Dates of Depo-Provera or depo-subQ provera 104
  injections, even
• OB/GYN, clinic, pharmacy, or insurance records showing
  the shots.
• The date you were diagnosed with a meningioma.
• MRI, CT, pathology, neurosurgery, radiation oncology, or
  neurology
• Notes showing symptoms that led to the diagnosis, such
  as headaches,
• Records for surgery, radiation, hospitalization, or
  ongoing

If the injections were years ago, start with the places
that kept the paper trail: the clinic, pharmacy, insurer,
or patient portal. Old appointment calendars and billing
statements can also help jog your memory.

Who may want to ask questions now

A case review may make sense if you used Depo-Provera or a
related medroxyprogesterone acetate injectable
contraceptive and later received a meningioma diagnosis.
Longer use, repeated injections, tumor location, surgery,
ongoing symptoms, and the timing between use and diagnosis
may matter.

Some facts can make a claim harder. Examples include a
meningioma diagnosis that came before the injections,
missing exposure records, a different tumor type, or only
very limited use. That does not mean you should guess
alone. It means the screening needs to be careful.

Where things stand in July 2026

The Depo-Provera meningioma MDL is active and large.
JPML's July 1 report lists 5,830 pending federal actions.
The FDA label now includes a meningioma warning for these
medroxyprogesterone acetate products. The science and
expert evidence remain central to what happens next.

For families, the best move is boring but useful: collect
the prescription and medical records, write down the
timeline while it is fresh, and get a review based on the
actual facts. Headlines cannot do that part for you.

This article is attorney advertising and is for
informational purposes only. It is not medical advice. It
is not a guarantee of compensation, settlement, or any
legal result. Talk with a qualified healthcare
professional about medical questions and with a licensed
attorney about your legal rights.

Sources checked

• JPML, Pending MDLs and July 1, 2026 actions-pending
  report for MDL No.
• FDA-approved Depo-Provera CI and depo-subQ provera 104
  labeling,
• PubMed/BMJ, "Use of progestogens and the risk of
  intracranial
• Cleveland Clinic, "Meningioma: What It Is, Symptoms &
  Treatment."
• Lawsuit Information Center, "Depo Provera Lawsuit
  Settlement: July